Efficacy of levetiracetam as first-line therapy for neonatal clinical seizures and neurodevelopmental outcome at 12 months of age.
Anticonvulsants
/ pharmacology
Child Development
/ drug effects
Cross-Sectional Studies
Electroencephalography
/ methods
Follow-Up Studies
Humans
Infant
Infant, Newborn
Infant, Newborn, Diseases
/ drug therapy
Infant, Premature
/ growth & development
Levetiracetam
/ pharmacology
Retrospective Studies
Seizures
/ drug therapy
Treatment Outcome
First-line therapy
Levetiracetam
Neonatal seizure
Neurodevelopmental outcome
Prematurity
Journal
Acta neurologica Belgica
ISSN: 2240-2993
Titre abrégé: Acta Neurol Belg
Pays: Italy
ID NLM: 0247035
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
30
12
2019
accepted:
24
04
2020
pubmed:
20
5
2020
medline:
23
2
2022
entrez:
20
5
2020
Statut:
ppublish
Résumé
Appropriate treatment of neonatal seizures with an effective therapy is important in reducing long-term neurologic disabilities. Sixty-seven neonates, who received intravenous (IV) levetiracetam (LEV) as first-line therapy for treating seizures between 2013 and 2017 were evaluated retrospectively to investigate the efficacy of LEV and its neurodevelopmental outcome at 12 months of age. Of the 67 neonates (44 preterm and 23 term babies) evaluated for seizures, 55 (82%) had a defined etiology. EEG confirmation was obtained in 36 (57.1%) of the neonates with clinical seizures. On the 7th day of the treatment (mean seizure control time 7.4 ± 15.1 days), LEV was effective as monotherapy in 43 (64%), whereas add-on therapy was required in 24 (36%) neonates. At the 1-year follow-up, 76% of infants achieved drug-free state, nine (18%) infants remained on LEV monotherapy and three (6%) needed add-on therapy. Neurodevelopmental outcome of the infants was assessed with Ankara Development Screening Inventory and results suggested favorable neurodevelopmental outcome in 69.7% of the infants with at the end of the 1-year follow-up with LEV monotherapy. In conclusion, this retrospective cross-sectional study demonstrated that IV LEV is an effective first-line therapy for treating neonatal clinical seizures and LEV monotherapy effect was sustained during the first year follow-up.
Identifiants
pubmed: 32424740
doi: 10.1007/s13760-020-01366-7
pii: 10.1007/s13760-020-01366-7
doi:
Substances chimiques
Anticonvulsants
0
Levetiracetam
44YRR34555
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1495-1503Informations de copyright
© 2020. Belgian Neurological Society.
Références
Silverstein FS, Jensen FE (2007) Neonatal seizures. Ann Neurol 62:112–120. https://doi.org/10.1002/ana.21167
doi: 10.1002/ana.21167
pubmed: 17683087
Kharoshankaya L, Stevenson NJ, Livingstone V et al (2016) Seizure burden and neurodevelopmental outcome in neonates with hypoxic-ischemic encephalopathy. Dev Med Child Neurol 58:1242–1248. https://doi.org/10.1111/dmcn.13215
doi: 10.1111/dmcn.13215
pubmed: 27595841
pmcid: 5214689
Pisani F, Spagnoli C (2015) Neonatal seizures: a review of outcomes and outcome predictors. Neuropediatrics 47:012–019. https://doi.org/10.1055/s-0035-1567873
doi: 10.1055/s-0035-1567873
Bartha AI, Shen J, Katz KH et al (2007) Neonatal seizures: multicenter variability in current treatment practices. Pediatr Neurol 37:85–90. https://doi.org/10.1016/j.pediatrneurol.2007.04.003
doi: 10.1016/j.pediatrneurol.2007.04.003
pubmed: 17675022
Hmaimess G, Kadhim H, Nassogne M-C et al (2006) Levetiracetam in a neonate with malignant migrating partial seizures. Pediatr Neurol 34:55–59. https://doi.org/10.1016/j.pediatrneurol.2005.06.011
doi: 10.1016/j.pediatrneurol.2005.06.011
pubmed: 16376281
Khan O, Cipriani C, Wright C et al (2013) Role of intravenous levetiracetam for acute seizure management in preterm neonates. Pediatr Neurol 49:340–343. https://doi.org/10.1016/j.pediatrneurol.2013.05.008
doi: 10.1016/j.pediatrneurol.2013.05.008
pubmed: 23921284
Khan O, Chang E, Cipriani C et al (2011) Use of intravenous levetiracetam for management of acute seizures in neonates. Pediatr Neurol 44:265–269. https://doi.org/10.1016/j.pediatrneurol.2010.11.005
doi: 10.1016/j.pediatrneurol.2010.11.005
pubmed: 21397167
Loiacono G, Masci M, Zaccara G, Verrotti A (2016) The treatment of neonatal seizures: focus on levetiracetam. J Maternal Fetal Neonatal Med 29:69–74. https://doi.org/10.3109/14767058.2014.986651
doi: 10.3109/14767058.2014.986651
Sedighi M, Asadi F, Moradian N et al (2016) Efficacy and safety of levetiracetam in the management of seizures in neonates. Neurosciences (Riyadh, Saudi Arabia) 21:232–235
doi: 10.17712/nsj.2016.3.20150726
Lloreda-García JM, Fernández-Fructuoso JR, Gómez-Santos E et al (2017) Uso de levetiracetam en crisis convulsivas neonatales. Anales de Pediatría 86:286–288. https://doi.org/10.1016/j.anpedi.2016.08.004
doi: 10.1016/j.anpedi.2016.08.004
pubmed: 27743966
Tanriverdi S, Terek D, Koroglu OA et al (2013) Neonatal status epilepticus controlled with levetiracetam at Sturge Weber syndrome. Brain Develop 35:367–371. https://doi.org/10.1016/j.braindev.2012.06.005
doi: 10.1016/j.braindev.2012.06.005
Fürwentsches A, Bussmann C, Ramantani G et al (2010) Levetiracetam in the treatment of neonatal seizures: a pilot study. Seizure 19:185–189. https://doi.org/10.1016/j.seizure.2010.01.003
doi: 10.1016/j.seizure.2010.01.003
pubmed: 20133173
Ramantani G, Ikonomidou C, Walter B et al (2011) Levetiracetam: safety and efficacy in neonatal seizures. Euro J Paediatric Neurol 15:1–7. https://doi.org/10.1016/j.ejpn.2010.10.003
doi: 10.1016/j.ejpn.2010.10.003
Abend NS, Gutierrez-Colina AM, Monk HM et al (2011) Levetiracetam for treatment of neonatal seizures. J Child Neurol 26:465–470. https://doi.org/10.1177/0883073810384263
doi: 10.1177/0883073810384263
pubmed: 21233461
pmcid: 3082578
Sharpe CM, Capparelli EV, Mower A et al (2012) A seven-day study of the pharmacokinetics of intravenous levetiracetam in neonates: marked changes in pharmacokinetics occur during the first week of life. Pediatr Res 72:43–49. https://doi.org/10.1038/pr.2012.51
doi: 10.1038/pr.2012.51
pubmed: 22495532
Rakshasbhuvankar A, Rao S, Kohan R et al (2013) Intravenous levetiracetam for treatment of neonatal seizures. J Clin Neurosci 20:1165–1167. https://doi.org/10.1016/j.jocn.2012.08.014
doi: 10.1016/j.jocn.2012.08.014
pubmed: 23664133
Neininger M, Ullmann M, Dahse A et al (2015) Use of levetiracetam in neonates in clinical practice: a retrospective study at a german university hospital. Neuropediatrics 46:329–334. https://doi.org/10.1055/s-0035-1558969
doi: 10.1055/s-0035-1558969
pubmed: 26308219
Volpe JJ (1989) Neonatal seizures: current concepts and revised classification. Pediatrics 84:422–428
pubmed: 2671912
Pressler R, Cilio M, Mizrahi E, Moshé S (2017) The ILAE classification of seizures & the epilepsies: modification for seizures in the neonate. Proposal from the ILAE Task Force on Neonatal Seizures
Pavlidis E, Spagnoli C, Pelosi A et al (2015) Neonatal status epilepticus: differences between preterm and term newborns. Euro J Paediatric Neurol 19:314–319. https://doi.org/10.1016/j.ejpn.2015.01.002
doi: 10.1016/j.ejpn.2015.01.002
Tekgul H, Bourgeois BFD, Gauvreau K, Bergin AM (2005) Electroencephalography in neonatal seizures: comparison of a reduced and a full 10/20 montage. Pediatr Neurol 32:155–161. https://doi.org/10.1016/j.pediatrneurol.2004.09.014
doi: 10.1016/j.pediatrneurol.2004.09.014
pubmed: 15730894
Holmes GL, Lombroso CT (1993) Prognostic value of background patterns in the neonatal EEG. Journal Clin Neurophysiol 10:323–352
doi: 10.1097/00004691-199307000-00008
Tekgul H, Gauvreau K, Soul J et al (2006) The Current etiologic profile and neurodevelopmental outcome of seizures in term newborn infants. Pediatrics 117:1270–1280. https://doi.org/10.1542/peds.2005-1178
doi: 10.1542/peds.2005-1178
pubmed: 16585324
Mizrahi EM, Chapman KE (2004) Neonatal seizures and postneonatal epilepsy—causes. In: Shorvon SD, Andermann F, Guerrini R (eds) The causes of epilepsy. Cambridge University Press, Cambridge, pp 373–381
Falsaperla R, Vitaliti G, Mauceri L et al (2017) Levetiracetam in neonatal seizures as first-line treatment: a prospective study. J Pediatric Neurosci 12:24–28. https://doi.org/10.4103/jpn.JPN_172_16
doi: 10.4103/jpn.JPN_172_16
Han JY, Moon CJ, Youn YA et al (2018) Efficacy of levetiracetam for neonatal seizures in preterm infants. BMC Pediatrics 18:131. https://doi.org/10.1186/s12887-018-1103-1
doi: 10.1186/s12887-018-1103-1
pubmed: 29636029
pmcid: 5892045
Booth D, Evans DJ (2004) Anticonvulsants for neonates with seizures. Cochrane Database Syst Rev 4:CD004218. https://doi.org/10.1002/14651858.CD004218.pub2
doi: 10.1002/14651858.CD004218.pub2
World Health Organization. Department of Mental Health and Substance Abuse, Agarwal R, World Health Organization. Department of Maternal N, OASI Institute for Research and Prevention of Mental Retardation (Troina IU of N and CN Guidelines on neonatal seizures
McHugh D, Lancaster S, Manganas L (2018) A Systematic review of the efficacy of levetiracetam in neonatal seizures. Neuropediatrics 49:012–017. https://doi.org/10.1055/s-0037-1608653
doi: 10.1055/s-0037-1608653
Guidelines on Neonatal Seizures IRCCS Associazione Oasi Maria SS. World Health Organization
Saini A, Vinayan K (2018) Status epilepticus in neonates. Int J Epilepsy 05:002–008. https://doi.org/10.1055/s-0038-1667213
doi: 10.1055/s-0038-1667213
Yau ML-Y, Fung EL-W, Ng PC (2015) Response of levetiracetam in neonatal seizures. World J Clin Pediatrics 4:45–49. https://doi.org/10.5409/wjcp.v4.i3.45
doi: 10.5409/wjcp.v4.i3.45
Maitre NL, Smolinsky C, Slaughter JC, Stark AR (2013) Adverse neurodevelopmental outcomes after exposure to phenobarbital and levetiracetam for the treatment of neonatal seizures. J Perinatol 33:841–846. https://doi.org/10.1038/jp.2013.116
doi: 10.1038/jp.2013.116
pubmed: 24051577
pmcid: 4000307